Please try another search
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People’s Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Peili Wang | - | 2023 | Executive Director |
Peili Wang | 39 | 2014 | Financial Manager & Executive Director |
Sheung Wai Chan | 69 | 2020 | Independent Non-Executive Director |
Yunqing Wang | 38 | 2020 | CFO, Joint Company Secretary & Executive Director |
Li Wang | 55 | 2014 | Executive Chairman of the Board, CEO & GM |
Xubo Lu | 42 | 2020 | Independent Non-Executive Director |
Wing Yiu Djen | - | 2023 | Independent Non-Executive Director |
Junyi Wang | 34 | 2023 | Employee Representative Supervisor |
Tao Cai | 37 | 2020 | Chairperson of the Board of Supervisors & Head of Technology of BRS |
Lei Zhu | 38 | 2022 | Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review